UA103154C2 - Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його - Google Patents

Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його

Info

Publication number
UA103154C2
UA103154C2 UAA200907944A UAA200907944A UA103154C2 UA 103154 C2 UA103154 C2 UA 103154C2 UA A200907944 A UAA200907944 A UA A200907944A UA A200907944 A UAA200907944 A UA A200907944A UA 103154 C2 UA103154 C2 UA 103154C2
Authority
UA
Ukraine
Prior art keywords
peptide
hla
amino acid
restricted
pharmaceutical composition
Prior art date
Application number
UAA200907944A
Other languages
English (en)
Russian (ru)
Inventor
Харуо Сугіяма
Original Assignee
Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк. filed Critical Інтернешнл Інстітьют Оф Кенсер Іммунолоджи, Інк.
Publication of UA103154C2 publication Critical patent/UA103154C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Винахід належить до пептиду, здатному зв'язуватися з молекулою HLA-A* 1101 і здатному індукувати цитотоксичний Т-лімфоцит (CTL), який складається з амінокислотної послідовності Thr Gly Val Lys Pro Phe Gin Cys Lys (SEQ ID NО:7), в якій від однієї амінокислоти до п'яти амінокислот можуть бути заміщені іншою (ими) амінокислотою (ами), а також до фармацевтичної композиції для лікування або профілактики злоякісного новоутворення, яка містить зазначений поліпептид, до способу індукції WT1-специфічного цитотоксичного Т-лімфоцита, набору, що містить зазначений поліпептид.
UAA200907944A 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його UA103154C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28
PCT/JP2007/074146 WO2008081701A1 (ja) 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Publications (1)

Publication Number Publication Date
UA103154C2 true UA103154C2 (uk) 2013-09-25

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200907944A UA103154C2 (uk) 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його

Country Status (28)

Country Link
US (4) US8653038B2 (uk)
EP (6) EP2341142B8 (uk)
JP (1) JP5484734B2 (uk)
KR (1) KR101525261B1 (uk)
CN (5) CN102302788B (uk)
AR (1) AR064555A1 (uk)
AU (1) AU2007340679B2 (uk)
BR (1) BRPI0720988A2 (uk)
CA (5) CA2886619A1 (uk)
CY (1) CY1116011T1 (uk)
DK (3) DK2479276T3 (uk)
ES (4) ES2526425T3 (uk)
HK (3) HK1159686A1 (uk)
IL (4) IL199052A0 (uk)
MX (1) MX2009007008A (uk)
MY (1) MY161664A (uk)
NO (1) NO20092774L (uk)
NZ (4) NZ592510A (uk)
PH (1) PH12014500902A1 (uk)
PL (1) PL2341142T3 (uk)
PT (1) PT2341142E (uk)
RU (1) RU2481398C2 (uk)
SG (1) SG177222A1 (uk)
SI (1) SI2341142T1 (uk)
TW (3) TWI417103B (uk)
UA (1) UA103154C2 (uk)
WO (1) WO2008081701A1 (uk)
ZA (1) ZA200903633B (uk)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513563C (zh) 2003-11-05 2009-07-15 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
JP2009511637A (ja) 2005-10-17 2009-03-19 スローン−ケターリング インスティチュート フォー キャンサー リサーチ Ｈｌａクラスｉｉ結合ｗｔ１ペプチド及びその組成物、並びにその作成方法
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
RU2680539C2 (ru) 2007-02-27 2019-02-22 Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. Способ активации хелперных т-клеток и композиция для применения в данном способе
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
SG193956A1 (en) * 2011-04-01 2013-11-29 Sloan Kettering Inst Cancer T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
KR20140083986A (ko) 2011-09-14 2014-07-04 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 항wt1 항체의 측정 방법
CN108676069A (zh) 2012-01-13 2018-10-19 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
SG11201504558TA (en) 2012-12-11 2015-07-30 Einstein Coll Med Methods for high throughput receptor:ligand identification
US9833493B2 (en) * 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
CN110078813B (zh) 2013-01-15 2023-03-28 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
KR102045029B1 (ko) 2013-02-05 2019-11-14 닛토덴코 가부시키가이샤 점막 투여용 ｗｔ1 펩티드 암 백신 조성물
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
KR20140100422A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 백신 조성물
CA2840974A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
CA2840954A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
JP6440360B2 (ja) 2013-02-05 2018-12-19 日東電工株式会社 経皮投与用ワクチン組成物
US10588952B2 (en) * 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
KR102121638B1 (ko) 2013-03-29 2020-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Wt1 항원 펩티드 콘쥬게이트 백신
WO2016093326A1 (ja) 2014-12-11 2016-06-16 株式会社癌免疫研究所 血管新生病の免疫療法
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP2019522466A (ja) 2016-05-18 2019-08-15 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド 変異ｐｄ−ｌ１ポリペプチド、ｔ細胞調節多量体ポリペプチド、及びそれらの使用方法
CN116970061A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
MX2022014249A (es) * 2020-05-12 2023-02-22 Sumitomo Pharma Co Ltd Composición farmacéutica para tratar el cáncer.
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
MY139226A (en) * 1998-09-30 2009-08-28 Corixa Corp Compositions and methods for wt1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
EP1169347B1 (en) * 1999-04-02 2008-07-02 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030082194A1 (en) * 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
ATE466084T1 (de) 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
MXPA04012642A (es) * 2002-06-14 2005-03-23 Merck & Co Inc Inhibidores de la cinesina mitotica.
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JP4498274B2 (ja) 2003-01-15 2010-07-07 株式会社癌免疫研究所 二量体化ペプチド
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
EP2186896B1 (en) 2004-03-31 2015-11-04 International Institute of Cancer Immunology, Inc. Cancer antigen peptides derived from WT1
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP4719876B2 (ja) * 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring

Also Published As

Publication number Publication date
CN102335439A (zh) 2012-02-01
CA2886622A1 (en) 2008-07-10
ES2526425T3 (es) 2015-01-12
EP2341142A3 (en) 2011-09-07
CN102302788B (zh) 2016-06-15
IL215332A0 (en) 2011-11-30
CN101573448A (zh) 2009-11-04
ES2629578T3 (es) 2017-08-11
IL199052A0 (en) 2010-03-28
CN102302788A (zh) 2012-01-04
US9272026B2 (en) 2016-03-01
EP2098595A4 (en) 2010-03-17
AU2007340679B2 (en) 2013-09-12
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
US20140134200A1 (en) 2014-05-15
EP2341142A2 (en) 2011-07-06
NZ592509A (en) 2012-11-30
TWI554280B (zh) 2016-10-21
AU2007340679A1 (en) 2008-07-10
NZ592510A (en) 2012-11-30
US20160199472A1 (en) 2016-07-14
ES2554775T3 (es) 2015-12-23
TW201345544A (zh) 2013-11-16
PT2341142E (pt) 2015-02-13
TWI417103B (zh) 2013-12-01
CA2886619A1 (en) 2008-07-10
EP2980219A1 (en) 2016-02-03
KR101525261B1 (ko) 2015-06-02
EP3026115B1 (en) 2017-05-17
TWI599367B (zh) 2017-09-21
IL215334A0 (en) 2011-11-30
US20180064795A1 (en) 2018-03-08
DK2479275T3 (en) 2015-12-14
SG177222A1 (en) 2012-01-30
NZ577443A (en) 2011-12-22
CN102335439B (zh) 2015-04-22
EP2980219B1 (en) 2018-11-14
SI2341142T1 (sl) 2015-03-31
CN101573448B (zh) 2012-07-11
NO20092774L (no) 2009-07-27
IL215333A0 (en) 2011-11-30
PH12014500902B1 (en) 2016-01-11
EP2098595A1 (en) 2009-09-09
MY161664A (en) 2017-04-28
ES2556831T3 (es) 2016-01-20
EP3026115A1 (en) 2016-06-01
US8653038B2 (en) 2014-02-18
PH12014500902A1 (en) 2016-01-11
CN102659924A (zh) 2012-09-12
ZA200903633B (en) 2010-02-24
MX2009007008A (es) 2009-07-10
EP2341142B1 (en) 2014-11-26
CN102659924B (zh) 2015-11-25
NZ601175A (en) 2012-12-21
BRPI0720988A2 (pt) 2014-03-18
US20110098233A1 (en) 2011-04-28
CA2886621A1 (en) 2008-07-10
PL2341142T3 (pl) 2015-04-30
HK1159686A1 (en) 2012-08-03
WO2008081701A1 (ja) 2008-07-10
HK1173187A1 (zh) 2013-05-10
RU2481398C2 (ru) 2013-05-10
CA2886620A1 (en) 2008-07-10
TW201630620A (zh) 2016-09-01
DK2479276T3 (en) 2015-12-21
EP2479275A1 (en) 2012-07-25
EP2479275B1 (en) 2015-10-28
KR20090102772A (ko) 2009-09-30
EP2479276A1 (en) 2012-07-25
JP5484734B2 (ja) 2014-05-07
DK2341142T3 (en) 2014-12-08
JPWO2008081701A1 (ja) 2010-04-30
RU2009128979A (ru) 2011-02-10
CA2670658A1 (en) 2008-07-10
CY1116011T1 (el) 2017-01-25
CN102295682A (zh) 2011-12-28
AR064555A1 (es) 2009-04-08
HK1221252A1 (zh) 2017-05-26
TW200835513A (en) 2008-09-01

Similar Documents

Publication Publication Date Title
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
MXPA06001283A (es) Derivados de insulina novedosos.
CY1113117T1 (el) Ηlα-α*3303-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση η οποια περιλαμβανει αυτο το ιδιο
WO2009004315A8 (en) Isolated peptides and uses thereof
MX2008009493A (es) Peptido novedoso y uso del mismo.
WO2006087550A3 (en) Amyloid-binding peptides, analogues and uses thereof
BRPI0718996B8 (pt) método para a preparação de um peptídio da fórmula h-d-?-nal-[cys-tyr-d-trp-lys-val-cys]-thr-nh2 ou h-d-?-nal-cys(acm)-tyr-d-trp-lys-val-cys(acm)-thr
EP2039367A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT FOR NEURODEGENERATIVE DISEASES
MX353301B (es) Composiciones tripeptidicas y metodos para tratamiento de diabetes.
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
MX2020010520A (es) Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas.
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
MX2011012742A (es) Compuestos depuradores de metilglioxal y su uso para la prevencion y tratamiento de dolor y/o hiperalgesia.
WO2010011994A3 (en) Polypeptides and uses thereof
WO2006097748A3 (en) Peptide stabilizer compounds and screening method
MY126118A (en) Somatostatin analogs for the treatment of cancer
WO2007066018A3 (fr) Peptides qui peuvent se lier a la proteine nef et leurs applications pharmaceutiques
EP3771719A8 (en) A peptide binding to tau-protein
EP1730174A4 (en) PEPTIDE CARRIER FOR THE ADMINISTRATION OF MEDICINAL PRODUCTS
DE60018937D1 (de) Somatostatin analoge und deren verwendung zur behandlung von krebs